Innate Pharma (IPHA) EBITDA (2019 - 2025)
Innate Pharma (IPHA) reported EBITDA of -$60.9 million for Q4 2025, down 6.59% on a YoY basis from -$65.2 million in Q4 2024, and down 111.5% quarter-over-quarter from -$28.8 million in Q2 2025.
Innate Pharma (IPHA) EBITDA (2019 - 2025) Analysis & Trends
Innate Pharma has reported EBITDA for 7 years, with the latest figure at -$60.9 million in Q4 2025.
- For the quarter ending Q4 2025, EBITDA fell 6.59% year-over-year to -$60.9 million; the trailing twelve-month figure through Dec 2025 stood at -$175.1 million (down 82.4% YoY), and the FY2025 full-year result was -$62.9 million, down 14.07% from the prior year.
- EBITDA for Q4 2025 stood at -$60.9 million, down from -$28.8 million in the prior quarter.
- The five-year high for EBITDA was $7.5 million in Q2 2021, with the low at -$60.9 million in Q4 2025.
- Historically, EBITDA has averaged -$25.9 million across 5 years, with a median of -$28.3 million in 2024.
- Annual changes were most pronounced in 2021 — EBITDA jumped 181.84% — and 2023, when it plunged 15570.6%.
- Innate Pharma's EBITDA stood at -$54.7 million in 2021, then surged by 99.88% to -$64574.5 in 2022, then sank by 15570.6% to -$10.1 million in 2023, then slumped by 464.39% to -$57.1 million in 2024, then retreated by 6.59% to -$60.9 million in 2025.
- The last three EBITDA figures came in at -$60.9 million (Q4 2025), -$28.8 million (Q2 2025), and -$57.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - | -60.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -60.88 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Dec 31, 2024 | -57.11 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Dec 31, 2023 | -10.12 Mn |
| Jun 30, 2023 | -433,391.91 |
| Dec 31, 2022 | -64,574.52 |
| Dec 31, 2021 | -54.71 Mn |
| Jun 30, 2021 | 7.53 Mn |
| Dec 31, 2020 | -9.05 Mn |
| Jun 30, 2020 | -9.19 Mn |
| Dec 31, 2019 | -28.49 Mn |